Old school journalistic values are still important: it’s vital to try to preserve objectivity and distance from your subject and sources. You may not always achieve it, but you don’t throw these values away willy-nilly.
Then comes TV news ratings/sweeps periods.
KSTP-TV in Minneapolis began a two-part series on one of their reporter’s ovarian cancer last night, two days into a new ratings period. I’m quoted in the Star Tribune criticizing the decision. Station executives use predictable defenses to justify their decision.
What’s not in the paper are some of my other concerns:
1. Who says her case is representative of other cancer patients or even of other ovarian cancer patients? Then why is it newsworthy?
2. Why is it newsworthy? What editorial decision-making took place to lift her story to air worthiness? What’s the last story they did on ovarian cancer? Does it take someone on the on-air staff being diagnosed with something to get a station to report on it? What were the factors that made this newsworthy?
3. In weighing newsworthiness before a sweeps period, did they give any thought to covering the 20-30,000 Minnesotans who might lost MinnesotaCare coverage under current legislative proposals? Are the 30,000 less important than the one in-house story?
4. The station says that there is important public education to be achieved by publicizing such a case. If that’s so, what was the last story they did on ovarian cancer prior to this?
This is not an isolated case. It’s just the latest of many, in which TV people think their celebrity status is at such a level that their stories rise to newsworthiness, whereas the plight of the great unwashed remain unknown.
Opinions on other issues in news, journals, PR, advertising, marketing
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like